Condition: Relapsed/Refractory Multiple Myeloma · Sponsor: Nanjing Leads Biolabs Co.,Ltd
This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with Relapsed/Refractory Multiple Myeloma (R/R MM).
This description comes directly from the study's public registry record.
jin lu · 025-83378099 · mengdongtao@leadsbiolabs.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Wannan Medical College | Wuhu, Anhui, China | Recruiting |
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University Shougang Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Not Yet Recruiting |
| The First Affiliated Hospital of Xiamen University | Xiamen, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Shenzhen Second People's Hospital | Shenzhen, Guangdong, China | Recruiting |
| The Afliliated Hospital of Guizhou Medical Univeristy | Guiyang, Guizhou, China | Recruiting |
| The Second Affiliated Hospital of Hainan Medical University | Haikou, Hainan, China | Recruiting |
| The First Affiliated Hospital of Henan University | Luoyang, Henan, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Not Yet Recruiting |
+ 14 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06049290